Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Operating Cash Flow
Cash generated by the company's core business operations during the period.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $1.77M (cash outflow) rose 105.5% year over year, ahead of the +15.1% change in trailing-twelve-month operating cash flow. Sequentially, it rose 47.6% from the prior quarter. Over 3 fiscal years it compounded at +98.9% a year.
Context
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +105.5% holds above the trailing-twelve-month pace of +15.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (3.69M) USD
- Year-over-year change
- +27.3%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.69M) | +27.3% |
| FY2024 | 2024-12-31 | (5.07M) | -31.4% |
| FY2023 | 2023-12-31 | (3.86M) | -723.6% |
| FY2022 | 2022-12-31 | (468.66K) | -292.5% |
| FY2021 | 2021-12-31 | (119.4K) | — |
Operating Cash Flow vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's LTM Mar 2026 operating cash flow of $4.6M is the smallest of the 6 companies compared; the peer median is $19.17M.
- Its year-over-year change of +15.1% is the highest of 6, against a peer median of -17.5%.
- Over three fiscal years its annual growth of +98.9% compares with a peer median of +15.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $94.5M | -17.5% | — | — | |
| LTM Mar 2026 | $59.11M | -51.8% | -20.4% | 39.1% | |
| LTM Mar 2026 | $19.17M | -41.4% | -0.2% | — | |
| LTM Mar 2026 | $18.88M | +2.6% | +37.6% | — | |
| LTM Mar 2026 | $8M | +12.4% | +30.4% | 565.5% | |
| LTM Mar 2026 | $4.6M | +15.1% | +98.9% | — | |
| Peer median (excluding TELO) | $19.17M | -17.5% | +15.1% | 302.3% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Depreciation & Amortization | 0 | 0 | 0 | 4.34M | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 6.87M | 5.29M |
| Change in Working Capital | 18.74K | 385.49K | 113.84K | 126.47K | 594.69K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 18.74K | 0 | 114.56K | 183.63K | (50.77K) |
| Other Working Capital | 18.74K | 385.49K | (713) | (57.16K) | 645.46K |
| Other Non-Cash Items | 0 | 385.49K | 9.1M | 130K | 840K |
| Operating Cash Flow | (119.4K) | (468.66K) | (3.86M) | (5.07M) | (3.69M) |
| Capital Expenditures | (4) | 0 | (4) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 462.39K | 3.17M | (101K) | 0 |
| Common Stock Issued | 0 | 0 | 1M | 6.83M | 9.55M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 119.4K | 7.69K | (310.38K) | (396.65K) | 155.52K |
| Financing Cash Flow | 119.4K | 470.08K | 3.86M | 6.34M | 9.71M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 1.42K | (188) | 1.26M | 6.02M |
| Free Cash Flow | (119.4K) | (468.66K) | (3.86M) | (5.07M) | (3.69M) |
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.